Skip to main content
CTOS 2025 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Lu Xie

Deputy Medical Director
Musculoskeletal Tumor Centre, Peking University People's Hospital, China (People's Republic)

Lu Xie
Medical and Pediatric Oncologist for Sarcoma
Deputy Medical Director, Musculoskeletal Tumor Center
Clinical Associate Professor, Master supervisor, Peking University
She conducted many trials for target therapy for advaced osteosarcoma, such as apatinib or Apatinib plus
camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial and so on. She would much love to devote herself into the tumor microenviroment for osteosarcoma.

Poster(s):